This is a competitive renewal application for training grant support in pediatric oncology. The goal of this T32 program is to train physicians who will be the future academic leaders in basic and/or clinical pediatric oncology research and who will work to reduce the burden of cancer in the pediatric population. To accomplish this goal we have engaged a diverse and outstanding training faculty that embraces multiple areas of basic (""""""""wet bench""""""""), translational and clinical research. This experienced and highly accomplished group includes members of the Department of Pediatric Oncology at the Dana-Farber Cancer Institute (DFCI), the Division of Pediatric Hematology/Oncology at Boston Children's Hospital (BCH), and additional components of the Harvard Medical School (HMS). Particular emphasis is placed on close mentorship of trainees in the selection of mentors and in on-going oversight during their research. The T32 program provides training in oncology research at the postdoctoral level for 8 trainees, selected from the combined DFCI-BCH pediatric hematology/oncology fellowship program, who are in their second, third and fourth years of training. The program is committed to identifying and supporting the most promising fellows, including minority candidates. Over the past 45 years the DFCI-BCH fellowship program has trained over 200 individuals, many of whom are leaders of academic pediatric hematology/oncology programs. Continued T32 support will ensure the training of investigational pediatric oncologists, whose research will contribute immeasurably to the understanding and management of childhood cancers.
While great strides have been made in the diagnosis and treatment of pediatric cancers, much remains to be done. Cure of patient is often achieved with unacceptable side-effects, and for many solid tumors current therapy is inadequate. The best hope for reducing the burden of pediatric cancer is the training of committed researchers by an experienced and accomplished faculty that is involved in diverse aspects of basic and clinical research directly relevant to tackling these challenging problems in children.
|Venkatramani, Rajkumar; Pan, Hubert; Furman, Wayne L et al. (2016) Multimodality Treatment of Pediatric Esthesioneuroblastoma. Pediatr Blood Cancer 63:465-70|
|Hong, Andrew L; Tseng, Yuen-Yi; Cowley, Glenn S et al. (2016) Integrated genetic and pharmacologic interrogation of rare cancers. Nat Commun 7:11987|
|Greenzang, Katie A; Cronin, Angel M; Mack, Jennifer W (2016) Parental preparedness for late effects and long-term quality of life in survivors of childhood cancer. Cancer 122:2587-94|
|Wu, Shuo-Chieh; Li, Loretta S; Kopp, Nadja et al. (2015) Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. Cancer Cell 28:29-41|
|Marron, Jonathan M; Mack, Jennifer W (2015) When to say when: How aggressively to care for children with multiply relapsed cancer? Pediatr Blood Cancer 62:1119-20|
|Wu, Jennifer N; Pinello, Luca; Yissachar, Elinor et al. (2015) Functionally distinct patterns of nucleosome remodeling at enhancers in glucocorticoid-treated acute lymphoblastic leukemia. Epigenetics Chromatin 8:53|
|Mar, Brenton G; Bullinger, Lars B; McLean, Kathleen M et al. (2014) Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. Nat Commun 5:3469|
|Kamihara, Junne; Rana, Huma Q; Garber, Judy E (2014) Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome. Hum Mutat 35:654-62|
|Wang, Leo D; Wagers, Amy J (2011) Dynamic niches in the origination and differentiation of haematopoietic stem cells. Nat Rev Mol Cell Biol 12:643-55|